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Pterodon pubescens Benth., popularly known as “sucupira”, is traditionally used as pain healing 
agent for many inflammatory diseases. The present study evaluated the in vivo antinociceptive 
and anti-inflammatory properties of sucupira’s fruit dicloromethane extract (Pp) compared to the 
aqueous extract (Ppa) traditionally used in folk medicine. Extracts’ chemical characterization was 
performed by gas chromatography coupled to mass spectra (GC-MS) detection. The standardized 
extracts were evaluated using antinociceptive and anti-inflammatory experimental models with 
mice. The results reported herein allowed establishing a relationship between the popular use of 
Pterodon pubescens fruit for pain relief and the activity of two major compounds isolated from 
this species which demonstrated antinociceptive activity. The experimental models corroborate 
activity of aqueous extract antinociceptive and anti-inflammatory activity, with lower potency 
compared to dichloromethane extract. Nevertheless the resulting data corroborates sucupira’s 
folk use for pain relief.
Keywords: Pterodon pubescens Benth., antinociceptive, furanditerpenes, sucupira, biological 
and pharmacological activities
Introduction
The study of inflammatory pain has been one of the most 
rapidly advancing and expanding areas of pain research. 
The chronic rheumatoid arthritis affects approximately 
0.5-1% of the population, being among the main causes 
of adult disabilities characterized by spontaneity as well 
as lowered pain thresholds and increased sensitivity to 
pressure and temperature.1-5 Chronic pain differs from acute 
pain not only in onset and duration, but more importantly 
in the underlying mechanisms, poorly responding to the 
usual drugs for acute pain. In order to improve chronic 
pain diseases treatment, a clear understanding of what 
leads to such persistent pain (visceral, inflammatory, and 
neuropathic) is required. Therefore testing pharmacological 
agents in such settings is the best way to explore new drug 
leads for chronic pain relief. An important source for this 
purpose is medicinal plants.6
Pterodon pubescens’ fruit decoction is widely used 
in Brazilian folk medicine for treatment of several 
chronic diseases such as rheumatism and arthritis.7,8 
The pharmacological properties of extracts, fractions 
and compounds obtained from P. pubescens have been 
reported for anti-parasitic, antitumor, anti-inflammatory, 
and antinociceptive activities.7-25 However, there is no 
scientific evidence reported concerning the antinociceptive 
and anti-inflammatory effectiveness of the aqueous 
extract or data supporting the ethno pharmacological 
use. Therefore, herein the differences in chemical profile, 
in vivo analgesic and anti-inflammatory properties of 
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the dichloromethane P. pubescens fruit extract (Pp) and 
aqueous P. pubescens fruit extract (Ppa) is reported. 
The extracts’ pharmacological efficiency and chemical 
profile were determined to support the species use for oral 
pain treatment. These results are indispensable for the 
production of effective and standardized herbal extracts 
aiming the development of herbal medicines.8,23,24
Experimental
Pterodon pubescens fruit were previously collected in 
Minas Gerais State (Ponto Chique City), in September 2011 
and identified by Prof Dr Jorge Yoshio Tamashiro from 
IB-UNICAMP (Department of Botany), who identified 
the plant species. A voucher specimen was deposited at the 
University of Campinas (UNICAMP) Herbarium, under 
number 179740. Access to genetic resources (CGEN) was 
authorized under process number 010495/2012-6.
Freeze-dried fruit (100 g) were ground prior to use 
in a Stephen mill (model UM 40) and extracted with 
dichloromethane by soxhlet extraction system using a 
1:3 ratio on mass basis (ground fruit:solvent). Subsequently 
the extract was concentrated under vacuum (Buchi RE 120) 
yielding 32% crude extract. The aqueous extract was 
produced by extraction with a reflux system using a 
1:25 ratio on mass basis (ground fruit:H2O). Extraction was 
carried out for a period of 1 hour after water started boiling. 
The solution was cooled to room temperature, concentrated 
under vacuum (Buchi RE 120) and freeze dried (Virtis®, 
Model 8L) yielding 14% crude aqueous extract.
The gas chromatography-mass spectrometry (GC-MS) 
analysis was carried out using a HP-6890/5975 system 
equipped with a J&W Scientific DB-5 fused capillary 
column (25 m × 0.2 mm × 0.33 m). Temperature program: 
60 °C (5 °C min-1) to 300 °C (10 min), injector 250 °C, 
detector 300 °C. Helium was used as carrier gas (0.7 bars, 
1 mL min-1). The MS were taken at 70 eV. Scanning speed 
was 0.84 scans s-1, from 40 to 550. Sample volume was 
1 μL. Split: 1:40.
Relative abundance of 6α,7β-dihydroxyvouacapan-
17β-oate methyl ester and isomers 6α-hydroxy-7β-
acetoxy-vouacapan-17β-oate methyl ester and 6α-acetoxy-
7β-hydroxy-vouacapan-17β-oate methyl ester and 
geranylgeraniol in crude P. pubescens extract were 
measured by area normalization method. The Pp analysis 
determined 3.7% of 6α,7β-dihydroxyvouacapan-17β-oate 
methyl ester; 9.0% of 6α-acetoxy-7β-hydroxy-vouacapan-
17β-oate methyl ester; 12% of 6α,7β-dihydroxyvouacapan-
17β-oate methyl ester; and 9.3% of geranylgeraniol. 
The Ppa extract analysis determined 11.7% of 6α,7β-
dihydroxyvouacapan-17β-oate methyl ester; 7.0% of 
6α-acetoxy-7β-hydroxy-vouacapan-17β-oate methyl ester; 
9.6% of 6α,7β-dihydroxyvouacapan-17β-oate methyl ester; 
and absence of geranylgeraniol content under analysis 
conditions employed. Standards were previously isolated 
from dichloromethane P. pubescens fruit crude extract, 
comparing spectral data to that of authentic samples 
reported previously.15,22
Male Swiss mice and male Wistar rats with 25-35 g 
and 200-250 g body weight, respectively, were kept at 
25 ± 2 °C in 12 h light-dark cycles (light phase started at 
7:00 am), maintained (mice: 10 animals per cage; rats: 
5 animals per cage) with water and food ad libitum, at least 
for 7 days prior to assays. Animals were fasted 12 hours 
prior to oral administration of compounds, in order to 
avoid possible pharmacokinetic interactions. Separate mice 
groups were used for each analgesic test and administration 
route. Animals were used only once in acute experiments. 
Studies were carried out in accordance with current 
guidelines for the veterinary care of laboratory animals 
and were performed under the consent and surveillance of 
UNICAMP’s Institute of Biology Ethics Committee for 
Animal Research (2367-1).26
All drugs and extracts were diluted in 1% Tween 80® 
vehicle (Sigma-Aldrich, USA) in 0.9% saline solution 
(NaCl diluted in distilled water). The following substances 
were used: dexamethasone (Sigma-Aldrich, USA), 
pentobarbital, (Cristália, Brazil), acetic acid, carrageenan 
(Sigma-Aldrich, USA), complete Freund adjuvant (Sigma-
Aldrich, USA), and formaldehyde (Chemco, Brazil).
The ambulatory behavior was assessed in an open-field 
test as previously described.8 The apparatus consisted of 
a plastic box measuring 45 × 45 × 20 cm, with the floor 
divided into 9 equal squares (15 × 15 cm). The number 
of squares crossed with all paws (crossing) was counted 
in a 3 min session. Mice were 60 min previously treated 
orally (p.o.) with dichloromethane P. pubescens fruit 
extract (Pp) and aqueous P. pubescens fruit extract (Ppa) 
(30, 100 and 300 mg kg-1), pentobarbital (35 mg kg-1) 
or vehicle. Results were expressed as mean ± S.E.M. of 
6 animals per group.
The writhing test was carried out as described 
previously.27,28 Groups of mice (n = 6) were treated 
orally (p.o.) with vehicle (10 mL kg-1), dichloromethane 
P. pubescens fruit extract (Pp) and aqueous P. pubescens 
fruit extract (Ppa) using three doses 10, 30, and 100 mg kg-1. 
Writhing was induced by an i.P. injection of 0.8% acetic 
acid solution (0.1 mL 10 g-1), 60 min afterwards. The 
numbers of writhing (abdominal constrictions) were 
cumulatively counted over 15 minutes, for nociception 
evaluation. Data represent the average of the total writhing 
observed per dose concentration.
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Formalin-induced nociception was measured as 
previously described.28,29 Groups of mice (n = 6) 
were treated orally (p.o.) with vehicle (10 mg kg-1), 
dichloromethane P. pubescens fruit extract (Pp) and 
aqueous P. pubescens fruit extract (Ppa) using 30, 100, 
and 300 mg kg-1 doses. For nociception induction, animals 
received 20 μL intraplantar injection of a 2% formaline 
solution (formaldehyde in saline solution, 0.9% NaCl 
and distilled water) in the ventral surface of the right 
hind paw, 60 min after treatments. Animals were then 
observed for 30 min, between 0 and 5 min represented 
the neurogenic (early) phase, and between 15 and 30 min 
represented the inflammatory (late) phase. The time the 
animals spent licking or biting the injected paw was 
recorded as indicative of nociception. The reduction of 
time that treated group spent licking the paw compared 
to the control group was considered expression of 
antinociceptive activity.
The procedures used for this study were similar to those 
described previously by Winter et al.,30 with some changes 
in the protocol and data analysis. The animals received 
100 μL saline (0.9%) intraplantar injections into the right 
hind paw containing carrageenan (300 μg paw-1). The 
animals were pretreated p.o. with vehicle (control group) 
and Pp and Ppa extracts (30, 100 and 300 mg kg-1), 60 min 
prior to edema induction. The paw edema thickness was 
measured using a plethysmometer (Ugo Basile, Italy) 2, 4 
and 6 h after edema induction. All of the assessments were 
performed by the same investigator in order to reduce any 
potential inter-operator differences.
The procedures used for this study were similar to 
those described previously by Spindola et al.23 with some 
changes in the protocol and data analysis. Different groups 
of rats (n = 6) were submitted to pressure stimulus (0 to 
500 g) on the right hind paw using an analgesy-meter (Ugo 
Basile, Italy) prior to carrageenan injection, in order to 
determine the basal value. The hyper nociceptive response 
was considered when animals vocalized or withdrew the 
paw from the equipment, demonstrating pain. After this 
first measurement, animals received a carrageenan (0.1 mL) 
intraplantar (i.pl.) injection (2.5% in saline) into the right 
hind paw surface. After 2.5 h, they were submitted to 
pressure again, to evaluate whether the hyper nociceptive 
state was reached (40% decrease). Animals were then 
treated with vehicle (10 mL kg-1, i.p., negative control), 
Pp and Ppa extracts (30, 100 and 300 mg kg-1, p.o.), with 
mechanical hyperalgesia measurement evaluated after 2 
and 3 h. The value demonstrating mechanical hyperalgesia 
was obtained after each measurement, and the results were 
shown as decreased percentage compared to the pressure 
tolerated in the basal (100%) value for each group.
The complete Freund’s adjuvant (CFA) solution 
(1 mg mL-1 of heat killed Mycobacterium tuberculosis 
in 85% paraffin oil and 15% mannide monooleate) was 
used to produce chronic inflammation and arthritis in 
rats. The procedures used for this study were similar to 
those described previously by Omura et al.31 with some 
changes in the protocol and data analysis. The rats received 
100 μL of CFA intraplantar injection into the right hind 
paw. The daily oral treatments began 7 days after CFA 
injection during 14 days (enough to reproduce arthritis), 
as follows: negative control (saline solution only), positive 
control (3 mg kg-1 dexamethasone), Pp extract (30, 100 and 
300 mg kg-1), and Ppa extract (30, 100 and 300 mg kg-1). 
Two different analyses were performed in order to measure 
the effectiveness of both extracts against CFA-induced 
arthritis. The arthritis index was determined by monitoring 
paw edema (swelling) with a digital plethysmometer (Ugo 
Basile, Italy) and calculated according to the formula: 
AI(%) = (injected paw volume – baseline volume) × 100 
baseline volume-1. The measurements were made on day 0 
(baseline before CFA-injection), and days 7, 14, and 21 
after CFA-injection. Results were analyzed comparing 
treated groups with negative control (saline). Mechanical 
allodynia was assessed using the dynamic plantar 
aesthesiometer apparatus (Ugo Basile, mod 37450, Italy) 
which consisted of an elevated wire mesh platform to allow 
access to the ventral surface of the hind paws. A steel rod 
(diameter 0.5 mm) was pushed against the hind paw with 
ascending force (touch stimulator). The force ranged from 
0 to 35 g over a 20 s period. When the animal withdrew 
the hind paw, the mechanical stimulus was automatically 
stopped, and the force applied in the animal to withdraw the 
paw was recorded to the nearest 0.1 g. The paw withdrawal 
threshold was measured after 4 consecutive stimuli into 
the injected paw. The measurements were made on day 0 
(baseline before CFA-injection), and days 7, 10, 14, and 
21 after CFA-injection. Results were analyzed comparing 
treated groups with negative control (saline).
All treated groups were compared with the control 
group and the results were analyzed statistically using 
one-way analysis of variance (ANOVA), followed by 
Duncan’s test to identify the differences between treated 
groups and control. The data were considered significant 
at p ≤ 0.05 level.
Results
The results on the open-field test demonstrated that oral 
(p.o.) treatment with both dichloromethane P. pubescens fruit 
extract (Pp) and aqueous P. pubescens fruit extract (Ppa) in 
a dose-dependent manner based on logarithmic scale (30, 
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100 and 300 mg kg-1) did not cause any significant changes 
in the ambulatory behavior of mice (not shown). However, 
the intraperitoneal (i.p.) treatment with the positive control 
pentobarbital (35 mg kg-1) significantly (p ≤ 0.001) reduced 
the locomotor activity of animals on this assay, compared 
to the group that received vehicle. These data validated the 
dose-response curves designed for this study, especially for 
the behavioral methods used for samples antinociceptive 
activity evaluation, avoiding results misinterpretation.
The dose-response curves observed in Figure 1, show 
the effectiveness of dichloromethane P. pubescens fruit 
extract (Pp) and aqueous P. pubescens fruit extract (Ppa) 
extracts on reducing the number of abdominal constrictions 
compared to control group (vehicle only, p.o.). Groups 
treated with 10, 30, and 100 mg kg-1 doses of Ppa extract 
(absence of geranylgeraniol), were effective in reducing 
writhing by 17, *54, and *49%, respectively, presenting 
ED50 (50% effective dose) = 33.5 mg kg-1 (*p ≤ 0.05). 
Whereas, groups treated with 10, 30, and 100 mg kg-1 
doses of Pp extract (presence of geranylgeraniol) decreased 
writhing by *54, *49, and **73%, respectively, presenting 
ED50 = 22.2 mg kg-1 (*p ≤ 0.05; **p ≤ 0.01). For these 
comparisons, a positive control was not needed.
Results presented in Figure 2 demonstrated both 
phases of formalin test when animals were treated p.o. 
with Ppa extract, 60 min prior to formalin injection. 
Compared to control group (vehicle), in the first neurogenic 
phase (0-5 min) only the 300 mg kg-1 dose decreased 
significantly animals reaction time by 30% (*p ≤ 0.05). 
In the second inflammatory phase (15-30 min), the 
extract demonstrated effectiveness under a dose-response 
manner, reducing reaction time by **48% and ***86%, 
with 100 and 300 mg kg-1 doses, respectively, presenting 
ED50 = 114.1 mg kg-1 (**p ≤ 0.01; ***p ≤ 0.001). Treatment 
evaluation with Pp extract in the same assay is demonstrated 
in Figure 3 where, in the first phase the extract was more 
effective than Ppa extract, decreasing the reaction time by 
*36, 23, and *58%, under 30, 100, and 300 mg kg-1 doses, 
respectively (*p ≤ 0.05). Moreover, in the second phase Pp 
extract decreased the reaction time by 8, **50, and ***99%, 
with 30, 100 and 300 mg kg-1 doses, respectively, presenting 
ED50 = 89.8 mg kg-1 (**p ≤ 0.01; ***p ≤ 0.001).
The anti-inflammatory properties of both extracts are 
shown in Figure 4. Higher effectiveness of Pp compared to 
Figure 2. Graph demonstrating Ppa extract effects on licking induced by 
formalin in mice. Animals were treated with vehicle, Ppa (30, 100 and 
300 mg kg-1 doses; p.o.) prior to formalin. The total time spent licking the 
hind paw was measured in the first and second phase after intraplantar 
injection of formalin. Each column represents the mean ± S.E.M. of up 
to 6 mice in each group (*p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.001).
Figure 3. Graph demonstrating Pp extract effects on licking induced by 
formalin in mice. Animals were treated with vehicle, Pp (30, 100 and 
300 mg kg-1 doses; p.o.) prior to formalin. The total time spent licking 
the hindpaw was measured in the first and second phase after intraplantar 
injection of formalin. Each column represents the mean ± S.E.M. of up to 
6 mice in each group (*p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.001).
Figure 1. Abdominal constrictions induced by acetic acid (0.8% in saline) 
in mice previously treated (60 min) p.o. with control vehicle (10 mL kg-1), 
or Pp and Ppa extracts (10, 30, and 100 mg kg-1 doses; p.o.). Each column 
represents the mean ± S.E.M. of up to 6 animals for experimental groups 
(*p ≤ 0.05, **p ≤ 0.01).
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Ppa extract on reducing paw edema in the acute phase of the 
experiment was observed, compared to the control group 
(vehicle). The p.o. treatment with 300 mg kg-1 of Ppa extract 
(Figure 4A), decreased significantly paw edema by *35 and 
*49%, 4 and 6 h after carrageenan injection respectively 
(*p ≤ 0.05). Whereas, p.o. treatment with 30, 100, and 
300 mg kg-1 of Pp extract (Figure 4B) significantly reduced 
paw edema 4 h (**48, **39, and **40%, respectively) and 
6 h (**39, **40, and **58%, respectively) post carrageenan 
injection (**p ≤ 0.01).
The results presented in Figure 5 show that p.o. 
treatment 60 min beforehand with both Ppa (A) and Pp (B) 
extracts produced significant anti-hyper nociceptive effects, 
increasing the percentage of stimulus compared to the 
control group (only vehicle 10 mg kg-1). All doses tested 
(30, 100, and 300 mg kg-1) were effective in this assay 
(*p ≤ 0.05; **p ≤ 0.01).
The results shown in Figures 6 and 7 demonstrate 
two different parameters analyzed in the same assay, 
in order to measure and compare the activity of the 
p.o. treatments with Ppa and Pp extracts in the CFA-
induced arthritis model: the arthritis index (paw joint 
edema) and mechanical allodynia (pain perception). The 
daily treatment with positive control dexamethasone 
(10 mg kg-1, p.o.) significantly reduced arthritis index by 
***74 and ***63%, 14 and 21 days after CFA injection. 
Graph presented in Figure 6A indicates that the daily 
treatment with Ppa (30, 100 and 300 mg kg-1 doses, p.o.) 
starting 7 days after CFA injection, reduced arthritis index 
by 30, 21, and 26%, respectively. These reductions were 
not significantly different from the negative control group 
(vehicle, 10 mL kg-1). Results in Figure 6B show that daily 
treatment with Pp extract (30, 100 and 300 mg kg-1 doses, 
p.o.) starting 7 days after CFA injection, significantly 
Figure 4. Effects of the p.o. treatment 60 min beforehand with Ppa (A) and Pp (B) extracts on the carrageenan-induced paw edema in mice. Results 
expressed as increased percentage in paw edema compared to the baseline volume, after inflammation induction. Each point represents the mean ± S.E.M. 
of up to 6 animals. The significance levels (*p ≤ 0.05 and **p ≤ 0.01) were compared with control groups (only vehicle, 10 mL kg-1).
Figure 5. Graphs demonstrating results of vocalization or paw withdrawal related to pressure exerted in the right hind paw in response to the hypernociception 
caused by injection of carrageenan (2.5%, 0.1 mL) in rats p.o. treated with Ppa (A) and Pp (B) 30, 100 and 300 mg kg-1 doses compared to the control group 
(vehicle). Results expressed as reduction percentage means ± S.E.M. of up to 6 animals for experimental groups compared to the basal values (considered 
100%) (*p ≤ 0.05, **p ≤ 0.01).
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reduced arthritis index on the 14th experimental day by 
**42, **38, and **42%, respectively (**p ≤ 0.01).
The mechanical allodynia assessments started on day 
10 after CFA injection. Measurements for positive control 
dexamethasone (10 mg kg-1) showed significant activity 
in all time points tested (***p ≤ 0.001). The results in 
Figure 7A demonstrate that daily p.o. treatment with 
Ppa (30, 100, and 300 mg kg-1 doses) were significantly 
active after 14th day with 100 and 300 mg kg-1 doses 
increasing withdrawal threshold by ***87 and ***86%, 
respectively. On 21st day, 300 mg kg-1 dose also increased 
withdrawal threshold significantly (***p ≤ 0.001). 
Figure 7B demonstrates that the daily administration of Pp 
(30, 100 and 300 mg kg-1 doses, p.o.) starting after 7 days 
of CFA-injection, increased the withdrawal threshold 
pressure since the 10th experimental day, by ***67, ***87, 
and ***90%, respectively. The significant effectiveness 
continued until the end of the experiment (21st day) with 
100 and 300 mg kg-1 doses.
Discussion
We previously reported antinociceptive properties 
of diterpenes isolated from the P. pubescens fruit, 
demonstrating that the main compounds related to the 
biological activities were cyclic diterpenes: 6α,7β-
dihydroxyvouacapan-17β-oate methyl ester, and isomers 
6α-hydroxy-7β-acetoxy-vouacapan-17β-oate methyl 
ester and 6α-acetoxy-7β-hydroxy-vouacapan-17β-oate 
methyl ester, and acyclic isoprenoid geranylgeraniol. 
These compounds demonstrated to play an important 
role in antinociceptive and anti-inflammatory properties 
attributed to P. pubescens fruit crude extract, possibly by 
synergism.8,23,24 In fact, the absence of geranylgeraniol in 
the composition of the crude aqueous P. pubescens fruit 
extract (Ppa) containing the same amount of the main 
cyclic diterpenes produced less antinociceptive activity in 
as the experimental animal models evaluated (Figure 9). 
Therefore, the most relevant findings of the present work 
Figure 6. Effects of the daily treatments with vehicle (10 mL kg-1), positive control dexamethasone (10 mg kg-1), Pp, and Ppa extracts (30, 100, and 
300 mg kg-1) on the CFA-induced arthritis model in rats. Results expressed as arthritis index percentage decreased, compared to the negative control group 
vehicle. Each point represents the mean ± S.E.M. of up to 6 animals (**p ≤ 0.01 and ***p ≤ 0.001).
Figure 7. Effects of daily treatments with vehicle (10 mL kg-1), positive control dexamethasone (10 mg kg-1), Pp, and Ppa extracts (30, 100, and 300 mg kg-1 
doses) on CFA-induced arthritis rat model. Results expressed as mechanical allodynia pressure (withdrawal threshold in grams), compared to the negative 
control group vehicle. Each point represents the mean ± S.E.M. of up to 6 animals (*p ≤ 0.05; **p ≤ 0.01; and ***p ≤ 0.001).
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were that: (i) chemically, the extracts showed important 
differences in chemical profile, the lack of geranylgeraniol 
in the aqueous P. pubescens fruit crude extract (Ppa) 
decreased the antinociceptive activity; (ii) the number of 
chemical-induced models performed were sufficient to 
determine differences in extracts efficiency against pain and 
inflammation; (iii) compared to the aqueous P. pubescens 
fruit crude extract (Ppa), the dichloromethane P. pubescens 
fruit crude extract (Pp) demonstrated a greater effectiveness 
in writhing-, formalin-, carrageenan-tests, and CFA-induced 
arthritis models; (iv) both extracts demonstrated the same 
statistical effectiveness against carrageenan-induced hyper 
nociception in rats; (v) the absence of geranylgeraniol in 
the aqueous P. pubescens fruit crude extract might explain 
the significant differences on the pharmacologic properties 
between Pp and Ppa extracts obtained from P. pubescens.
This work was conducted with classical animal models 
routinely performed in our laboratory, which can provide 
useful and essential systems designed for the evaluation 
of the basic properties against pain and inflammation.8,23,28 
We first evaluated whether both extracts could interfere in 
the ambulatory animals behavior, in order to exclude the 
possibility that their antinociceptive properties could have 
relationship with non-specific disturbances in the locomotor 
activity, avoiding misinterpretation of results. These 
alterations might be resulted from either brain activation, 
manifested as excitation/depression of central neurons, or a 
relaxant activity at the neuromuscular junction level.32 The 
results in the open-field test validated the antinociceptive 
results observed in the dose-response curves designed for 
this study, considering that even the highest dosage tested 
did not interfere in the ambulatory animals’ behavior.
The acetic acid-induced abdominal constriction is a 
standard, simple, and sensitive test for measuring both 
central and peripheral induced analgesia. This test is 
commonly employed as a visceral inflammatory pain 
model.33 In acetic acid-induced abdominal constriction, 
pain is elicited by injection of an irritant such as acetic 
acid into the peritoneal cavity which produces episodes 
of characteristic stretching (writhing) movements and 
inhibition of number of episodes by analgesics is easily 
quantified.34 This is a convenient stimulus assay for 
screening, since the intensity of response depends on 
the interaction of several factors, neurotransmitters and 
Figure 8. Chemical structure of (1) 6α,7β-dihydroxyvouacapan-17β-oate 
methyl ester, (2) isomers 6α-hydroxy-7β-acetoxy-vouacapan-17β-oate 
methyl ester and 6α-acetoxy-7β-hydroxy-vouacapan-17β-oate methyl 
ester, and (3) acyclic isoprenoid geranylgeraniol.
Figure 9. GC-MS (HP6890/HP5975) normalized chromatograms of aqueous (A) and dichloromethane (B) extract. Compounds highlighted are geranylgeraniol 
(m/z 288), 6α,7β-dihydroxyvouacapan-17β-oate methyl ester (m/z 362) and isomers 6α-hydroxy-7β-acetoxy-vouacapan-17β-oate methyl ester (m/z 404 A) 
and 6α-acetoxy-7β-hydroxy-vouacapan-17β-oate methyl ester (m/z 404 B).
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neuromodulators that determine nociception (kinines, 
acetylcholine, P substance and prostaglandins). The acid 
acts indirectly by inducing mediator release, which stimulate 
the nociceptive neurons. Therefore this model is sensitive 
to drugs with analgesic activity possessing the most varied 
mechanisms of action, permitting antinociceptive activity 
evaluation caused by both neurogenic and/or inflammatory 
pain stimuli.35 On this experimental model, the oral 
treatment showed that Pp extract (ED50 22.5 mg kg -1) was 
32% more effective than Ppa extract (ED50 33.5 mg kg-1), 
and these differences have probably relationship with 
geranylgeraniol in Pp extract, corroborating our previous 
results which demonstrated the higher potency of 
geranylgeraniol given orally (ED50 26.7 mg kg-1), compared 
with the cyclic diterpenes 6α,7β-dihydroxyvouacapan-
17β-oate methyl ester (ED50 35.6 mg kg-1), and isomers 
6α-hydroxy-7β-acetoxy-vouacapan-17β-oate methyl ester 
and 6α-acetoxy-7β-hydroxy-vouacapan-17β-oate methyl 
ester (ED50 35.6 mg kg-1), in the same assay and route of 
administration.8,24 We also suggest that geranylgeraniol 
might increase Pp extract activity by acting peripherally 
via serotonergic and/or imidazoline systems, as described 
previously.23
The vanilloid family receptors, such as TRPV1, 
respond to protons that are found in a low-pH environment 
(chemical-induced pain), which can be caused by 
inflammation of surrounding tissues,36 therefore we further 
compared both Pp and Ppa extracts in formalin pain model, 
important to distinguish whether the extracts were able to 
decrease neurogenic (phase I) or inflammatory (phase II) 
pain stimuli. Neurogenic pain is caused by direct activation 
of nociceptive nerve terminals, whereas inflammatory 
pain is mediated by a combination of peripheral input and 
spinal cord sensitization. Formalin produces significant 
increase in spinal levels of different mediators related to 
both neurogenic (amino acids, kinins) and inflammatory 
pathways (prostaglandins, leukotrienes, cytokines). The 
tonic inflammatory pain induced by formalin, produced 
a distinct biphasic paw-flinching response that can be 
divided into phase I (0-10 min) and phase II (within 
40-60 min).37 The oral treatment with Pp and Ppa extracts 
significantly inhibited both the early and late phases of this 
test, demonstrating significant differences in effectiveness 
outcome. Pp extract was effective in the first phase, 
which is mediated by the direct chemical nociceptors 
activation. Whereas, Ppa extract did not show a significant 
activity in this phase, demonstrating the essential role 
of geranylgeraniol in the reduction of neurogenic pain 
stimuli induced by chemicals such as formalin. On the 
late phase II, both extracts demonstrated similar activity, 
suggesting that on the inflammatory response, the absence 
of geranylgeraniol did not interfere as much as expected. 
Thereupon we also explored how effective Pp and Ppa 
extracts could be in the inflammatory process caused by 
carrageenan injection, inducing edema and hyperalgesia 
in mice paw.
Inflammation is a multicellular process in which 
various types of cells, molecules, messengers, and 
plasma proteins participate in a highly effective and 
organized manner.38 Inflammatory response occurs in 
three distinct temporal phases, each mediated by different 
mechanisms: an acute phase characterized by transient 
vasodilatation and increased capillary permeability; a 
delayed sub-acute phase characterized by infiltration of 
leukocytes and phagocytic cells; a chronic proliferative 
phase in which tissue degeneration and fibrosis occur.39 
Many mechanisms are involved in the promotion and 
resolution of the inflammatory process and hyperalgesia.40,41 
Persistent and recurrent episodes of chronic inflammation 
mediated by activation of innate and acquired immunity 
is characteristic of a wide spectrum of idiopathic and 
infectious chronic inflammatory disorders.42 Some authors21 
demonstrated that P. pubescens’ ethanol extract, during an 
inflammatory episode, was able to suppress both cellular 
and humoral immune responses in lower concentrations 
compared to dexamethasone (immunosuppressant drug). 
The description of the influence of lupeol and botulin in 
the anti-inflammatory properties of ethanol extract were 
also reported.43 Our results demonstrated the influence 
of geranylgeraniol in the intensity of anti-inflammatory 
activity under edematogenic mechanisms. The early phase 
starts immediately after carrageenan injection and lasts for 
approximately 6 h, also leads to activation and secretion 
of mediators that include bradykinin and arachidonic acid 
metabolites such as prostaglandins and leukotrienes.44 
The participation of geranylgeraniol was represented by 
higher effectiveness of Pp extract on reducing paw edema 
in the acute phase of inflammatory process, compared to 
aqueous extract Ppa. These results motivated us to further 
explore whether both extracts could reduce hyperalgesia 
caused by carrageenan, in order to observe the potential 
of compounds to reduce not only edematogenic agents, 
but also pain associated with this process. Therefore, 
anti-hyper nociceptive effects of both extracts were 
evaluated in carrageenan-induced hyperalgesia, a model 
widely used for studying inflammation.39,45 In this model, 
carrageenan evokes a very inflammatory and nociceptive 
response characteristic, which is mediated by different 
groups of endogenous substances that stimulate chemo 
sensitive nociceptors, thus playing a major role in 
the development of inflammatory pain. Such process 
produces central sensitization in response to release 
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of pro-inflammatory mediators, which increase the 
sensitivity of peripheral and central sensory pathways.44 
These results corroborated late phase data in formalin 
test, with both extracts demonstrating similar activity on 
decreasing the inflammatory pain stimulus. Moreover, 
we also evaluated whether Pp and Ppa extracts could 
be active under an arthritis model in rats, based on the 
Pterodon pubescens’ folk medicine infusion commonly 
used for rheumatoid arthritis in humans, nevertheless with 
no scientific evidences for this ethno pharmacological 
knowledge. Rheumatoid arthritis (RA) is characterized by 
inflammatory cell infiltration and proliferation of synovial 
tissue, accompanied by bone destruction, and can quickly 
progress into multi system inflammation with irreversible 
joint damage causing premature mortality, disability, and 
compromised life quality.46,47 Pain, stiffness, swelling, 
deformity, and eventually joints function loss are common 
manifestations in RA.48 The disease is usually treated with 
anti-inflammatory and immunosuppressive drugs which 
cause important side effects, therefore new strategies 
for arthritis treatment are required. Medicinal plants 
are an important source of new leads for this purpose.49 
Sabino et al.50 reported treatment of collagen-induced 
arthritis in mice with P. pubescens’ seeds hydroalcoholic 
extract. CFA-induced arthritis in rats is a widely used 
experimental animal model of inflammatory polyarthritis 
characterized by infiltration of synovial membrane and 
associated with joints destruction, which resembles closely 
to those clinical and pathological features of human 
RA.50,51 Rats with adjuvant-induced arthritis (AA) are 
widely accepted as an appropriate model for screening 
potential anti-RA drugs.52 Our study demonstrated that Ppa 
extract which was deprived of geranylgeraniol content was 
effective in the measurement of mechanical allodynia, but 
not in paw swelling caused by CFA-injection. Whereas, 
Pp extract containing geranylgeraniol, demonstrated 
effectiveness in both evaluations decreasing mechanical 
allodynia and paw swelling compared to their control 
groups, in a dose-dependent manner.
Conclusions
Overall results presented herein corroborate traditional 
use of this species. Moreover our data highlighted the 
importance of geranylgeraniol to improve P. pubescens 
fruit extracts outcome against inflammatory pain. Further 
studies evaluating the potential of these extracts against 
neuropathic pain are in course. These data are in accordance 
with the hypothesis stating the potential use of these extracts 
in the treatment of chronic pain.
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